ELSI Fellows

ELSI Fellows 2021-2022

BlascoDrew Blasco- 1st Year Postdoctoral Fellow

Drew Blasco received her PhD in Public Health at New York University where she broadly focused on stigma related to mental health problems, including the implications of labeling individuals as ‘at-risk’ for future illness development (e.g. psychosis). During her doctoral studies she also researched conceptions of genetic risk regarding psychosis development and the implications of future genetic testing for psychosis among individuals identified as clinical high-risk for psychosis. An aspect of her dissertation explored the implications of having a family history of mental health problems, including stigma, among individuals at higher risk to develop psychosis. Prior to her PhD, she earned a master’s degree in Global Health from Arizona State University.

In her ELSI fellowship, Dr. Blasco is extending this work to genetic testing for Alzheimer’s disease and other later-life neuropsychiatric conditions, with mentorship from faculty mentors Dr. Roberts and Prof. Uhlmann. She has examined public perceptions of such testing using data from the UM National Poll on Healthy Aging. Dr. Blasco is currently preparing a K99/R00 career development award to examine use of genetic testing to inform drug treatment for AD, given that APOE4 carriers have elevated risk of side effects (e.g., brain microbleeds) from the recently FDA-approved therapy aducanumab.   

Sara FeldmanSara Feldman- 2nd Year Predoctoral Fellow

Sara Feldman is a current doctoral candidate at the University of Michigan School of Public Health. Sara earned her Master of Public Health degree from the University of Michigan School of Public Health in Health Behavior and Health Education in 2018.  She also has a Certificate in Injury Prevention through the University of Michigan School of Public Health and is working on completing a Certificate in Advanced Clinical Dementia Practice through the University of Michigan School of Social Work. Prior to attending the University of Michigan, Sara worked in domestic and international settings contributing to work in health education and promotion, disability education policy and advocacy, and case management for persons with disabilities.  She earned her Bachelor of Science degree in Human Development and Family Studies from The Pennsylvania State University.

Sara is vigorously interested in Alzheimer’s disease (AD), and with a keen interest in pre-clinical and early-stage disease (e.g., Mild Cognitive Impairment (MCI), mild AD). She is interested in the communication and disclosure of AD biomarker (e.g. amyloid, neurofibrillary tau tangles) and genetic (APOE, PSEN) information to persons at risk of AD and their family members. Additionally, with a strong focus on caregiver health and wellness, Sara seeks to understand the associated ethical, legal and social implications (ELSI) of AD genetic and biomarker information on family member pre-caregivers and caregivers of persons with pre-clinical AD and MCI who are at-risk of developing AD. The T32 fellowship has been instrumental in the development of her dissertation research plan, which will include both primary data collection and analysis of secondary data collected in the REVEAL trials. Her committee is chaired by Dr. Roberts and includes faculty mentor Prof. Uhlmann.

GeridoLynette Hammond Gerido- 1st Year Postdoctoral Fellow

Lynette Hammond Gerido is an information scientist using data and theory to investigate racial disparities, health behaviors, and precision medicine decisions. She received her PhD in Information from Florida State University. Her dissertation research explored trends in genetic screening for breast cancer to describe African American women’s genetic testing awareness and barriers accessing information and care.  Lynette has industry experience in technical program management, software engineering, web development, and visual communications for various federal and academic teams.

Prior to doctoral studies, she became immersed in health policy and disparities research while earning a Master of Business Administration at The George Washington University. She spent a summer abroad studying public-private partnerships in universal healthcare systems at the Universidade Federal da Bahia (UFBA), Brazil. She received a Master of Public Health and a B.S. in Bioscience from Drexel University. 

As an ELSI T32 postdoctoral fellow, Dr. Gerido has continued her focus on racial health inequities in cancer genetics services, becoming engaged with two NIH-funded studies exploring genetic testing of hereditary cancers: the MiGHT project under the mentorship of faculty mentors Drs. Stoffel, Hawley, and Resnicow, and the Genetic Information & Family Testing (GIFT) project under Drs. An and Hawley. A newly funded project of hers, supported by the UM Rogel Cancer Center, will identify information technology approaches to create culturally appropriate systems to 1) educate patients about genetic testing, 2) efficiently collect family history, and 3) explore communication needs within families to manage genetic knowledge. 

Katie HendyKatie Hendy- 3rd Year Postdoctoral Fellow

Dr. Katherine Hendy is a medical anthropologist and science studies scholar who uses ethnographic methods to investigate how biomedical knowledge produced in different settings--clinics, laboratories, and trials--is taken up by different groups of actors. Dr. Hendy has a Ph.D. from the University of California at Berkeley in sociocultural anthropology and a M.A. from the University of Chicago in the social sciences. Her doctoral research ethnographically followed the development of the drug MDMA—better known as the recreational drug “ecstasy”—as a treatment for posttraumatic stress disorder. Her research argues that the “outsider” status of MDMA-assisted therapy makes it a critical site for examining how claims about pharmaceutical safety and efficacy are produced and move between different experimental settings. Her dissertation and forthcoming publications track the development of a “documentary apparatus”--i.e. psychometric tests, protocols, and case report forms--that could transform New Age therapeutic techniques, embodied practices and subjective states into standardized, objective, bureaucratic evidence of MDMA’s efficacy and safety.

As a postdoctoral trainee in the ELSI program, Dr. Hendy is building upon her expertise in the ethnography of drug use and studies of scientific practice, to develop an ethnographic project on the ethical, legal, and social implications of the use of pharmacogenomics (PGx) in psychiatry. PGx  is a keystone of the Precision Health movement and has long promised to aid clinical decision making in order to lower adverse drug reactions and improve treatment outcomes. Private companies are increasing the availability of PGx tests for psychotropic medications through both direct to consumer platforms like 23andme and provider-guided tests such as Myriad Neuroscienc’s GeneSight. However, little is currently known about how patients and providers integrate this information into clinical care, or about how PGx intersects with other discussions of the nature of mental illness. While widely available and supported by health care groups--Medicare, the Veteran’s Administration, and several major insurance providers--the utility of these tests is still debated within psychiatry.  Dr. Hendy is developing an ethnographic study that would examine how patients and clinicians make decisions using an uncertain genomic test and how this genomic information intersects with larger discussions about the etiology of mental illness. To support this project, Dr. Hendy has successfully obtained funding through MICHR’s Postdoctoral Translational Scholars Program, mentored by faculty mentors Drs. Creary, Ellingrod, and Roberts. She is submitting a K99/R00 career development award application is June 2022 to the NHGRI ELSI program.

PleasantVersha Pleasant- 1st Year Postdoctoral Fellow

Dr. Versha Pleasant was born and raised in Philadelphia, Pennsylvania. She completed her undergraduate studies at the University of Virginia and received a BA in French, followed by an MPH at Yale University. She completed an HIV/AIDS Program Management Fellowship for the Centers for Disease Control and Prevention (CDC) in Rwanda and was later recruited to the CDC in Cote d'Ivoire to continue her work in HIV/AIDS among vulnerable populations such as orphans and commercial sex workers. After deciding to pursue a medical degree, she returned to the USA and continued health-consulting work while applying to medical school. She was accepted to the Georgetown Experimental Medical Studies Program, and subsequently matriculated to Georgetown School of Medicine where she graduated in 2016. Dr. Pleasant matched at the University of Michigan in Ob/GYN and completed residency in 2020. She then completed a fellowship in Cancer Genetics and Breast Health at the University of Michigan. She currently serves as the Director of the Cancer Genetics and Breast Health Clinic at VonVoigtlander Women’s Hospital at the University of Michigan. She provides medical and surgical care for hundreds of BRCA patients and others at increased risk for breast and ovarian cancer. She also provides specialized gynecologic care for breast cancer survivors.

Dr. Pleasant is also a post-doctoral fellow in the T32 Ethical, Legal and Social Implications of Genomics (ELSI) Research Training Fellowship at the University of Michigan. She is deeply interested in health disparities, particularly in breast cancer outcomes and genetic testing barriers facing Black women. With mentorship from faculty mentors Drs. Griggs and Stoffel, Dr. Pleasant is utilizing data from multiple cancer genetics clinics in the state of Michigan to examine racial disparities in uptake of BRCA testing. She is also interested in developing provider education tools to enhance knowledge of cancer genetic testing among OB/GYN professionals.  

Past Fellows

Amanda StanhausAmanda Stanhaus- Predoctoral Fellow 2019-2021

Dr. Amanda Stanhaus is a Health Management and Policy Ph.D. student at The University of Michigan and anticipates graduating soon with her PhD. Dr. Stanhaus is currently the Responsible Innovation Manager at Accenture as well as a Digital Trust Fellow at the World Economic Forum. Her current research is focused on societal implications of the metaverse and digital trust. 

While she has been a graduate student, she was awarded with NIH funding to explore her research interests of genetics, data privacy, and patient protection. Her research on the ethical implications of a blockchain-based electronic health record system can be found in the HIMSS Blockchain in Healthcare textbook.

Amanda’s advisor was Privacy Sociologist Professor Denise Anthony. Her faculty mentor for the ESLI fellowship was Professor Jodyn Platt. During Summer 2019, she was a visiting fellow at Cornell Tech as a research assistant to Privacy Philosopher Professor Helen Nissenbaum. Amanda served as a reviewer for the Journal of the American Medical Informatics Association and Blockchain in Healthcare Today.

Prior to her graduate studies at the University of Michigan, she worked as a strategist for J.P. Morgan’s Blockchain team that developed Quorum, a privacy-preserving version of Ethereum. As a research assistant to Yale University’s Professor Theodore Marmor, she analyzed Medicare during its 50th anniversary. And at McGill University, she worked with Dean Antonia Maioni to compare the welfare states of the U.S. and Canada while completing her B.A. in North American Studies and Economics.

Gracie TrinidadGrace Trinidad- Postdoctoral Fellow 2020-2021

Dr. Grace Trinidad received her PhD in Health Infrastructures and Learning Systems from the University of Michigan Medical School in 2020. She currently holds a position as the Director of the National Hemophilia Program Coordinating Center (NHPCC) of the American Thrombosis and Hemostasis Network.

Her dissertation work focused on where she examined the public’s comfort with sharing health data with third-party commercial companies and the relationship of this comfort with privacy concerns and trust in the health system. 

As a postdoctoral fellow in the ELSI program she researched patient privacy and the use of health data by third-party commercial companies with an exploration of user interface and user experience design approaches and their effect on patient privacy concerns. Her faculty mentors during the ELSI fellowship were Dr. Jodyn Platt and Professor Kayte Spector-Bagdady.

Her current research continues to explore health and data equity as well as the public’s comfort with sharing health data with third-party commercial companies as well as with university researchers. She continues to work with Professor Spector-Bagdady and Dr. Platt on data collection and publications and has also begun working with Dr. Melissa Creary to promote health equity research at the NHPCC.

Ellen Kim DeLucaEllen Kim DeLuca- Predoctoral Fellow 2018-2020

Ellen is currently a PhD candidate student in the Health Services Organization and Policy Program (cognate in Operations Research/Decision Sciences) in the Department of Health Management and Policy. In her dissertation, Ms. Kim is examining the cost-effectiveness of newborn screening for Krabbe disease, a serious childhood condition that is being screened for in several US states despite uncertain evidence of the utility of such screening. As a predoctoral fellow, Ellen's research focused on using mathematical modeling and decision making methods to evaluate maternal and child health policies in order to identify strategies that improve health outcomes. Her faculty mentors during the ELSI Fellowship were Drs. Prosser and Roberts.

Her current research includes modeling the ethical, legal, and social implications of genomics, specifically around evaluating the health and economic consequences of newborn screening of Krabbe disease. She is also developing a new health-related quality of life instrument for children: the PedsUtil scoring system. For her work on this instrument, she won the Anne Stiggelbout Award for Outstanding Presentation in Patient and Stakeholder Preferences and Engagement at the 43rd annual North American Meeting of the Society for Medical Decision Making.

Daniel Thiel y1Daniel Thiel- Predoctoral Fellow 2018-2020

Dr. Daniel Thiel was a Ph.D student in Sociology and Health Management and Policy (School of Public Health) at the University of Michigan. He graduated with his Ph.D. in 2020. He currently holds a faculty position at Michigan State University within its Lyman Briggs College, a science-focused college committed to connecting the natural sciences and mathematics with humanities and social sciences. Dr. Thiel will teach courses in its Bioethics minor and continue his ELSI research activities in collaboration with the MSU Center for Bioethics & Social Justice, housed in its College of Medicine. 

Dr. Thiel's dissertation project focused on the genome editing technology CRISPR-cas9 as a case of controversial, uncertain, promising technology that has implications for human health, but for which the technical, ethical, societal and policy questions have not yet been settled. 

During his time as an ELSI predoctoral fellow, Dr. Thiel worked on research projects related to the ethical, legal and social issues related to health data sharing and the role of race in genomics and public health. He was also involved in a project that was studying human resource professionals views of the Americans with Disabilities Act and workplace discrimination. His faculty mentors during the ELSI Fellowship were Drs. Kardia and Creary.

Selected ELSI Related Publications by U-M ELSI Fellows

Pleasant V, Ulrich N, Pearlman MD and Moravek MB, 2022, Reproductive Considerations for Patients with Early-Onset Breast Cancer, Current Breast Cancer Reports, 14:37–45
Hendy K, 2022, What Can the Chemical Hold?: The Politics of Efficacy in the Psychedelic Renaissance., Culture, Medicine and Psychiatry, 46:322-343
Amaral PS, Conte M, Flynn A, Platt J and Trinidad MG, 2022, Analysis of Pioneering Computable Biomedical Knowledge Repositories and their Emerging Governance Structures, Data Intelligence, 1-26
Hendy K, 2021, MDMA Is Not Ecstasy: The Production of Pharmaceutical Safety through Documents in Clinical Trials., Medical Anthropology Quarterly, 35:5-24
Largent EA, Abera M, Harkins K, Feldman SJ, Uhlmann WR, Roberts JS and Karlawish J, 2021, Family members' perspectives on learning cognitively unimpaired older adults' amyloid-β PET scan results., Journal of the American Geriatrics Society, 69:3203-3211
Stark L, Stanhaus A, and Anthony DL, 2020, A Universal Patient-Centric Electronic Health Record System: The Ethical Implications, Journal of the Association for Information Science and Technology, 71:1074-1088